Want to see ARTV full AI Analyst Report?
ARTV Stock Chart & Stats
$10.03
$0.57(5.68%)
At close: 4:00 PM EDT
$10.03
$0.57(5.68%)
Day’s Range― - ―
52-Week Range$2.22 - $14.53
Previous CloseN/A
Volume33.82K
Average Volume (3M)572.32K
Market Cap
$486.85M
Enterprise Value$234.99M
Total Cash (Recent Filing)$86.78M
Total Debt (Recent Filing)$10.26M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Aug 27, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding48,588,200
10 Day Avg. Volume428,090
30 Day Avg. Volume572,322
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-1.32
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-352.84
Enterprise Value/Ebitda-2.78
Forecast
1Y Price Target
$35.80Price Target Upside256.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy & Regulatory AlignmentRobust Phase 2a AlloNK signals (71% ACR50, deep B-cell depletion, no CRS/neurotoxicity) and FDA agreement on a single Phase 3 registrational trial materially reduce clinical and regulatory uncertainty. This de-risks development, clarifies endpoints and accelerates a coherent path toward registration and commercialization in refractory RA.
Material Capital RaiseA $300M underwritten equity offering meaningfully increases funding capacity, extending runway and enabling execution of planned Phase 3 programs. For a pre-revenue biopharma, this reduces near-term liquidity constraints and supports clinical milestones without immediate reliance on debt or milestone-dependent partner payments.
Modest LeverageLow absolute debt and a debt-to-equity ratio near 0.12 keeps interest burden and covenant risk low. For a clinical-stage company burning cash, modest leverage preserves strategic flexibility to fund R&D through equity or partnerships rather than servicing debt, supporting longer-term investment in clinical programs.
Bears Say
High Cash Burn, No Recurring RevenuePersistent, large negative operating and free cash flows with effectively no recurring revenue mean the business must repeatedly access capital to fund operations. This structural burn profile increases dilution risk, constrains strategic optionality and makes program continuity contingent on successful financings or partnerships.
Eroding Equity BaseRapid declines in shareholders' equity over recent periods reflect cumulative losses and capital depletion. A shrinking capital buffer reduces the company's ability to absorb clinical setbacks, increases the likelihood of future dilutive financings, and weakens bargaining power in partnership or licensing negotiations.
Executive Turnover And Role ConsolidationMultiple leadership shifts—board member moving into R&D leadership, CEO taking on principal financial duties, and CFO departure—create governance and execution risk during a critical Phase 3 transition. Consolidated roles may strain oversight and slow operational execution or strategic decisions.
Artiva Biotherapeutics, Inc. News
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $2.22 and its highest was $14.53 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Artiva Biotherapeutics, Inc.’s market cap is $486.85M.
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
Artiva Biotherapeutics, Inc.’s upcoming earnings report date is Aug 27, 2026 which is in 27 days.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Artiva Biotherapeutics, Inc. released its earnings results on May 08, 2026. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.87 by -$0.08.
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate is -0.63.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 48,588,200 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Artiva Biotherapeutics, Inc. reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.87. Following the earnings report the stock price went down -13.019%.
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artiva Biotherapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.80 (256.93% Upside)
$35.80 (256.93% Upside)
Blogger Sentiment
Bullish
ARTV Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $108.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
186.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-44.60%
Trailing 12-Months
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
ARTV Stock 12 Month Forecast
Average Price Target
$35.80
▲(256.93% Upside)
Technical Analysis
Adicet Bio
―
ABVC BioPharma
―
Jasper Therapeutics
―
Pliant Therapeutics
―
Repare Therapeutics
―
Ownership Overview
56.19% Insiders
1.17% Mutual Funds
0.25% Other Institutional Investors
39.62% Public Companies and
Individual Investors